Additionally, as we have introduced in the above section, cancer vaccines such as the HPV16 E6/E7 RNA-LPX vaccine combined with pembrolizumab are currently being evaluated in a phase II clinical trial for patients with HPV16+ and PDL1+ HNSCC (NCT04534205). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.